H.C. Wainwright analyst Yi Chen lowered the firm’s price target on First Wave BioPharma to $14 from $18 and keeps a Buy rating on the shares post the 2022 results. Management indicated that the Phase 2 SPAN trial of an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis is on track to report top-line results in mid-2023, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FWBI:
- First Wave BioPharma sells 1.02M shares at $3.91 per share
- First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis
- First Wave BioPharma announces second patient dosed in Phase 2 SPAN trial
- FWBI Rises on First Patient Dosing in Cystic Fibrosis Trial
- First Wave BioPharma announces first patient dosed in Phase 2 SPAN trial
